Stay updated on Duvelisib in Refractory Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.

Latest updates to the Duvelisib in Refractory Lymphoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedSignificant update: new operating-status notice and version bump to v3.2.0; previous v3.1.0 reference removed.SummaryDifference4%
- Check22 days agoChange DetectedUpdate: citation updated from v3.0.2 to v3.1.0 and addition of an erratum note; essentially a bibliographic metadata precision upgrade rather than a major content change.SummaryDifference0.5%
- Check37 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed; no substantive changes to core content.SummaryDifference0.2%
- Check44 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check51 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility names and locations, while removing several previous location entries and related medical topics.SummaryDifference3%
- Check58 days agoChange DetectedThe page has removed a significant study reference regarding Duvelisib in patients with refractory indolent non-Hodgkin lymphoma, which may impact the information available to readers about this treatment option.SummaryDifference0.4%
Stay in the know with updates to Duvelisib in Refractory Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Duvelisib in Refractory Lymphoma Clinical Trial page.